PinnyPeptide

GDF-8 95 (Myostatin Inhibitor) vs IGF-1 DES

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

GDF-8 95 (Myostatin Inhibitor)

Muscle Growth

Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway.

Peptide B

IGF-1 DES

Muscle Growth

Truncated IGF-1 variant — site-specific, short-acting muscle growth signal.

Typical vial

1 mg

Typical dose

50-200 mcg

Half-life

Variable / poorly characterized for short-peptide formulations

FDA status

Not FDA approved.

Typical vial

1 mg

Typical dose

20-100 mcg

Half-life

~20-30 minutes

FDA status

Not FDA approved.

GDF-8 95 (Myostatin Inhibitor) effects

  • Theoretical inhibition of myostatin signaling
  • Potential muscle hypertrophy via removal of myostatin brake
  • Limited direct evidence for short-peptide formulations in humans
  • Mechanistic rationale supported by pathway biology

IGF-1 DES effects

  • Strong acute IGF-1 receptor activation at the injection site
  • Promotes muscle cell hyperplasia (increased cell number)
  • Localized hypertrophy when injected intramuscularly
  • Faster clearance than IGF-1 LR3 (less systemic exposure)
  • Anabolic signaling via PI3K-Akt-mTOR

GDF-8 95 (Myostatin Inhibitor) side effects

  • Largely uncharacterized in humans
  • Theoretical: capillary leak if cross-reactivity with other TGF-β ligands occurs
  • Injection-site reactions
  • Possible immunogenicity (anti-drug antibody formation)

IGF-1 DES side effects

  • Localized hypertrophy / asymmetry if always injected in one site
  • Mild hypoglycemia (less than LR3)
  • Injection site discomfort or temporary muscle soreness
  • Theoretical IGF-driven proliferation concerns
  • Lipohypertrophy with repeated same-site injection

GDF-8 95 (Myostatin Inhibitor) dosing ranges

Research / muscle hypertrophy

50-200 mcg · Daily or twice-weekly (SubQ) · Per research protocol

IGF-1 DES dosing ranges

Site-specific muscle hypertrophy

20-50 mcg per site · Into trained muscle post-workout (IM) · 30-50 days per cycle

General anabolic support

50-100 mcg · Once daily (SubQ) · 30-50 days per cycle

Full GDF-8 95 (Myostatin Inhibitor) guide → Full IGF-1 DES guide →

GDF-8 95 (Myostatin Inhibitor) vs IGF-1 DES — common questions

What is the difference between GDF-8 95 (Myostatin Inhibitor) and IGF-1 DES?

GDF-8 95 (Myostatin Inhibitor): Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway. Typical dose 50-200 mcg. IGF-1 DES: Truncated IGF-1 variant — site-specific, short-acting muscle growth signal. Typical dose 20-100 mcg. Both fall under the Muscle Growth category.

Can you stack GDF-8 95 (Myostatin Inhibitor) and IGF-1 DES?

Stacking GDF-8 95 (Myostatin Inhibitor) with IGF-1 DES is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, GDF-8 95 (Myostatin Inhibitor) or IGF-1 DES?

GDF-8 95 (Myostatin Inhibitor) is typically dosed: Daily or twice-weekly (SubQ) for Research / muscle hypertrophy. IGF-1 DES is typically dosed: Into trained muscle post-workout (IM) for Site-specific muscle hypertrophy; Once daily (SubQ) for General anabolic support.

Are GDF-8 95 (Myostatin Inhibitor) and IGF-1 DES FDA approved?

GDF-8 95 (Myostatin Inhibitor): Not FDA approved. IGF-1 DES: Not FDA approved.

Related peptide comparisons

ace-031 vs gdf-8-95b7-33 vs gdf-8-95follistatin vs gdf-8-95gdf-8-95 vs igf-1-lr3ace-031 vs igf-1-desfollistatin vs igf-1-des

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free